Table 1.

Clinical characteristics of the patients with TLE

Case no.	Gender	Age (year)	Duration (year)	AEDs before surgery	Side focus	Seizure type	PO	Application
1	M	23	5	OXC, CBZ, VPA	RTN	FIAS	I	WB, IHC
2	M	18	5	OXC,VPA, PHT	LTN	FIAS	I	WB, IHC
3	M	24	9	OXC, CBZ, VPA, LTG	LTN	FAS/FBTCS	III	WB, IHC
4	F	29	14	CBZ, VPA, CBL	LTN	FAS/FBTCS	I	WB, IHC
5	F	31	12	OXC, CBL, VPA	LTN	FIAS	II	WB, IHC
6	M	19	5	OXC, VPA, GBP	RTN	FIAS	I	WB, IHC
7	M	31	10	CBZ, VPA, TPM	LTN	FIAS/FBTCS	III	WB, IHC
8	F	24	10	OXC, VPA, CBZ, PHT	RTN	FIAS	I	WB, IHC
9	F	21	5	OXC, PHT, LTG	LTN	FAS/FBTCS	II	WB, IHC
10	M	39	7	CBZ, VPA, CBL	RTN	FIAS	I	WB, IHC
11	F	31	11	CBZ, VPA, TPM	LTN	FAS	II	WB, IHC
12	M	24	13	OXC, VPA, PHT	RTN	FAS/FBTCS	I	WB, IHC
13	F	22	14	CBZ, PHT, VPA	RTN	FIAS	II	WB, IHC
14	F	19	5	OXC, VPA, PHT	RTN	FIAS/FBTCS	I	WB, IHC
15	F	27	8	VPA, PHT, TMP	LTN	FIAS	I	WB, IHC
16	M	41	20	OXC, CBZ, PHT, TMP	RTN	FAS	II	WB, IHC
17	F	31	16	CBZ, PHT, LTG	RTN	FAS/FBTCS	I	WB, IHC
18	M	28	11	VPA, CBZ, PHT	RTN	FIAS	II	WB, IHC
19	F	15	3	OXC, VPA, LTG	LTN	FIAS	I	WB, IHC
20	F	33	6	OXC, CBZ, LTG	LTN	FIAS/FBTCS	I	WB, IHC
21	M	37	15	OXC, CBL, VPA, TMP	LTN	FIAS	II	WB, IHC
22	F	29	12	OXC, VPA, LTG	RTN	FAS/FBTCS	II	WB, IHC

F female, M male, AED antiepileptic drugs, CBZ carbamazepine, VPA valproic acid, CLB clonazepam, GBP gabapentin, LTG lamotrigine, OXC oxcarbazepine, PB phenobarbital, PHT phenytoin, TPM topiramate, LTN left temporal neocortex, RTN right temporal neocortex, FIAS focal impaired awareness seizure, FAS focal aware seizures, FBTCS focal-to-bilateral tonic-clonic seizure, PO postoperative outcome (Engel class), WB western blotting, IHC immunohistochemistry